Geode Capital Management’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-131,112
| Closed | -$86K | – | 4157 |
|
|
2017
Q4 | $86K | Hold |
131,112
| – | – | ﹤0.01% | 3855 |
|
|
2017
Q3 | $41K | Hold |
131,112
| – | – | ﹤0.01% | 3962 |
|
|
2017
Q2 | $60K | Sell |
131,112
-2,564
| -2% | -$1.86K | ﹤0.01% | 3925 |
|
|
2017
Q1 | $160K | Buy |
133,676
+348
| +0.3% | +$435 | ﹤0.01% | 3720 |
|
|
2016
Q4 | $175K | Buy |
133,328
+9,894
| +8% | +$17.2K | ﹤0.01% | 3660 |
|
|
2016
Q3 | $257K | Buy |
123,434
+58
| +0% | +$115 | ﹤0.01% | 3511 |
|
|
2016
Q2 | $198K | Sell |
123,376
-24,097
| -16% | -$46.2K | ﹤0.01% | 3604 |
|
|
2016
Q1 | $143 | Buy |
147,473
+18,990
| +15% | +$18.5K | ﹤0.01% | 3731 |
|
|
2015
Q4 | $155K | Buy |
128,483
+116
| +0.1% | +$372 | ﹤0.01% | 3767 |
|
|
2015
Q3 | $953K | Buy |
128,367
+111
| +0.1% | +$849 | ﹤0.01% | 2899 |
|
|
2015
Q2 | $917K | Sell |
128,256
-6,119
| -5% | -$47.7K | ﹤0.01% | 2944 |
|
|
2015
Q1 | $1.15M | Buy |
134,375
+7,106
| +6% | +$63.6K | ﹤0.01% | 2791 |
|
|
2014
Q4 | $1.27M | Buy |
127,269
+7,509
| +6% | +$64K | ﹤0.01% | 2700 |
|
|
2014
Q3 | $1.19M | Buy |
119,760
+1,413
| +1% | +$20.9K | ﹤0.01% | 2687 |
|
|
2014
Q2 | $2.05M | Buy |
118,347
+1,092
| +0.9% | +$17.8K | ﹤0.01% | 2356 |
|
|
2014
Q1 | $2.08M | Buy |
117,255
+6,080
| +5% | +$118K | ﹤0.01% | 2309 |
|
|
2013
Q4 | $2.03M | Buy |
111,175
+8,610
| +8% | +$163K | ﹤0.01% | 2278 |
|
|
2013
Q3 | $2.75M | Buy |
102,565
+25,640
| +33% | +$549K | ﹤0.01% | 1981 |
|
|
2013
Q2 | $1.42M | Buy |
+76,925
| New | +$1.36M | ﹤0.01% | 2247 |
|
Geode Capital Management's RPRX Position: Q1 2018 in Review
Geode Capital Management sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 131,112 shares — an estimated $86K sold.
Geode Capital Management first reported a position in RPRX in Q2 2013 and held it in 19 quarters. The position peaked at $2.75M in Q3 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- Geode Capital Management reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- Geode Capital Management sold 131,112 Repros Therapeutics Inc. shares in Q1 2018, an estimated $86K.
- Geode Capital Management first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 19 quarters.
- Geode Capital Management's Repros Therapeutics Inc. position peaked at $2.75M in Q3 2013.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on Geode Capital Management's 13F filing for Q1 2018, filed 15 May 2018.